These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 19728784)
21. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
22. The economics of pediatric formulation development for off-patent drugs. Milne CP; Bruss JB Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801 [TBL] [Abstract][Full Text] [Related]
23. The translation of product concept to bone products: a partnership of therapeutic effectiveness and commercialization. Ratcliffe A Tissue Eng Part B Rev; 2011 Dec; 17(6):443-7. PubMed ID: 21790510 [TBL] [Abstract][Full Text] [Related]
24. Current regulatory issues in cell and tissue therapy. Burger SR Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234 [TBL] [Abstract][Full Text] [Related]
26. Characterization of gene therapy products and the impact of manufacturing changes on product comparability. Simek SL Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258 [TBL] [Abstract][Full Text] [Related]
27. FDA challenges stem-cell clinic. Cyranoski D Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009 [No Abstract] [Full Text] [Related]
28. Overview of the clinical application of regenerative medicine products in Japan. Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290 [TBL] [Abstract][Full Text] [Related]
29. Tissue engineering and regenerative medicine: role of toxicologic pathologists for an emerging medical technology. Jayo MJ; Watson DD; Wagner BJ; Bertram TA Toxicol Pathol; 2008 Jan; 36(1):92-6. PubMed ID: 18337226 [TBL] [Abstract][Full Text] [Related]
30. [The history and current status of clinical applications of stem cells]. Yamato M; Okano T Nihon Rinsho; 2011 Dec; 69(12):2103-8. PubMed ID: 22242305 [TBL] [Abstract][Full Text] [Related]
31. Development of vaccines for bio-warfare agents. Rosenthal SR; Clifford JC Dev Biol (Basel); 2002; 110():99-105. PubMed ID: 12477312 [TBL] [Abstract][Full Text] [Related]
33. Regenerative urology clinical trials: an ethical assessment of road blocks and solutions. Oerlemans AJ; Feitz WF; van Leeuwen E; Dekkers WJ Tissue Eng Part B Rev; 2013 Feb; 19(1):41-7. PubMed ID: 22784023 [TBL] [Abstract][Full Text] [Related]
34. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
35. [Diagnostic kits in parasitology: which controls?]. Rossi P Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705 [TBL] [Abstract][Full Text] [Related]
36. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. Knoben JE; Scott GR; Tonelli RJ Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285 [TBL] [Abstract][Full Text] [Related]
37. Regulatory barriers to tissue-engineered products. Schutte E Med Device Technol; 2002 Mar; 13(2):27-9. PubMed ID: 11984990 [TBL] [Abstract][Full Text] [Related]
38. Informing participants in clinical trials with ex vivo human tissue-engineered products: what to tell and how to tell it? Trommelmans L; Selling J; Dierickx K J Tissue Eng Regen Med; 2008 Jun; 2(4):236-41. PubMed ID: 18493918 [TBL] [Abstract][Full Text] [Related]
39. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880 [TBL] [Abstract][Full Text] [Related]